The incidence of osteonecrosis of the jaw (ONJ) among patients with cancer and metastatic bone disease being treated with bisphosphonates is as high as 10%, which dictates that an understanding of the risk factors, preventative measures, means of early diagnosis, and treatment is critical. Despite ONJ occurring in the clinical setting of intravenous bisphosphonates, there are other causes associated with higher risk of ONJ, such as multiple dental extractions. Overall, it is important for imaging health care professionals to recognize, describe, and understand ONJ to help minimize biopsies and allow proper treatment to begin as soon as possible.
From the *Division of Nuclear Medicine, Department of Radiology, †Department of Surgical and Hospital Dentistry, School of Dentistry, and ‡Department of Internal Medicine, University of Louisville, Louisville, KY.
Received for publication February 24, 2012; revision accepted August 9, 2012.
Conflicts of interest and sources of funding: none declared.
Reprints: A. Cahid Civelek, MD, Division of Nuclear Medicine, Department of Radiology, University of Louisville, 530 South Jackson St, Suite C07, Louisville, KY 40202. E-mail: firstname.lastname@example.org; and Geetika Bhatt, MD, Division of Nuclear Medicine, Department of Radiology, University of Louisville, 530 South Jackson St, Louisville, KY 40202, USA. E-mail: email@example.com